Matthew Fowler

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.

The combination of abiraterone acetate, prednisolone, and androgen deprivation therapy (ADT) with or without enzalutamide delivers a strong metastasis-free survival boost versus treatment with ADT alone in patients with high-risk non-metastatic prostate cancer.

"2 years of abiraterone-based therapy significantly improves metastasis-free survival and overall survival of high-risk nonmetastatic prostate cancer starting androgen deprivation therapy and should be now considered a new standard of care,” said Gerhardt Attard, MD, FRCP, PhD.

The combination achieved a high objective response rate among patients previously treated with immune checkpoint inhibitors.

Benefits in progression-free survival and overall response rate were also observed for the pembrolizumab/lenvatinib arm across risk-defined subgroups.

Ultra-high single-dose radiotherapy demonstrated comparable efficacy and safety as curative hypofractionated stereotactic body radiotherapy.

Role was highlighted in analysis of phase 3 PROSPER trial of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Investigational agents on the horizon include Vicineum, nadofaragene firadenovec, and N-803 (Anktiva).

The data demonstrate how the implementation of a telehealth pathway helped reverse the initial urologic-oncologic outpatient volume decline at an institution during the pandemic.

Cancer-specific survival is noninferior for active surveillance compared with primary intervention in select patients with small renal masses suspicious for renal cell carcinoma.

The researchers also determined that healthcare disparities were associated with cystectomy delay.